Solventum (NYSE:SOLV) Shares Unloaded Rep. J. French Hill

Representative J. French Hill (R-Arkansas) recently sold shares of Solventum Corporation (NYSE:SOLV). In a filing disclosed on January 23rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Solventum stock on December 31st. The trade occurred in the Representative’s “HILL 1998 TRUST” account.

Representative J. French Hill also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Kyndryl (NYSE:KD) on 12/31/2025.
• Sold $15,001 – $50,000 in shares of SFL (NYSE:SFL) on 12/31/2025.
• Sold $100,001 – $250,000 in shares of Pfizer (NYSE:PFE) on 12/31/2025.

Solventum Price Performance

Shares of SOLV stock traded up $0.35 during trading hours on Friday, hitting $76.87. The stock had a trading volume of 1,348,364 shares, compared to its average volume of 897,907. The stock has a market capitalization of $13.33 billion, a price-to-earnings ratio of 8.86, a PEG ratio of 7.03 and a beta of 0.34. The stock’s 50-day moving average price is $81.52 and its two-hundred day moving average price is $75.80. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. Solventum Corporation has a one year low of $60.70 and a one year high of $88.20.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The business had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The company’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum declared that its board has approved a stock repurchase plan on Thursday, November 20th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the company to reacquire up to 7.5% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. KeyCorp upgraded shares of Solventum from a “sector weight” rating to an “overweight” rating and set a $97.00 target price for the company in a report on Monday, January 26th. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Tuesday. Finally, Stifel Nicolaus increased their target price on Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $90.83.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Hilltop National Bank raised its stake in Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after acquiring an additional 129 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new stake in shares of Solventum in the third quarter worth about $25,000. Deseret Mutual Benefit Administrators boosted its holdings in Solventum by 78.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 370 shares of the company’s stock valued at $27,000 after purchasing an additional 163 shares during the period. JNBA Financial Advisors increased its stake in Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock worth $27,000 after acquiring an additional 228 shares during the last quarter. Finally, CYBER HORNET ETFs LLC purchased a new stake in Solventum in the second quarter valued at approximately $28,000.

About Representative Hill

French Hill (Republican Party) is a member of the U.S. House, representing Arkansas’ 2nd Congressional District. He assumed office on January 3, 2015. His current term ends on January 3, 2027.

Hill (Republican Party) is running for re-election to the U.S. House to represent Arkansas’ 2nd Congressional District. He declared candidacy for the 2026 election.

Hill is the founder and chairman of Delta Trust & Bank. He has served as senior policy advisor to President George H.W. Bush, Deputy Assistant Secretary of the U.S. Treasury and senior advisor to Governor Mike Huckabee.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.